Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David G Maggs

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Diabetes|June 29, 2011
Incretin-based therapiesAnthony H Stonehouse, Tamara Darsow, David G Maggs
Advances in Therapy|April 14, 2016
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical TrialsKathrin Herrmann, Steven C Brunell, Yan Li, et al.
Mayo Clinic Proceedings|March 7, 2015
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trialCarol H Wysham, Leigh A MacConell, David G Maggs, et al.
Obesity Research|April 20, 2004
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patientsPriscilla Hollander, David G Maggs, James A Ruggles, et al.
Diabetes Care|March 29, 2002
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesFred Whitehouse, Davida F Kruger, Mark Fineman, et al.
Diabetes/Metabolism Research and Reviews|January 23, 2004
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing studyDavid G Maggs, Mark Fineman, Jonathan Kornstein, et al.
Diabetes Care|March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialPriscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care|March 1, 2005
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetesAntonio Ceriello, Ludovica Piconi, Lisa Quagliaro, et al.
Diabetes/Metabolism Research and Reviews|April 25, 2006
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminMatthew C Riddle, Robert R Henry, Terri H Poon, et al.
Clinical Therapeutics|March 24, 2007
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsJohn B Buse, David C Klonoff, Loretta L Nielsen, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Diabetes|June 29, 2011
Incretin-based therapiesAnthony H Stonehouse, Tamara Darsow, David G Maggs
Advances in Therapy|April 14, 2016
Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical TrialsKathrin Herrmann, Steven C Brunell, Yan Li, et al.
Mayo Clinic Proceedings|March 7, 2015
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trialCarol H Wysham, Leigh A MacConell, David G Maggs, et al.
Obesity Research|April 20, 2004
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patientsPriscilla Hollander, David G Maggs, James A Ruggles, et al.
Diabetes Care|March 29, 2002
A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesFred Whitehouse, Davida F Kruger, Mark Fineman, et al.
Diabetes/Metabolism Research and Reviews|January 23, 2004
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing studyDavid G Maggs, Mark Fineman, Jonathan Kornstein, et al.
Diabetes Care|March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialPriscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care|March 1, 2005
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetesAntonio Ceriello, Ludovica Piconi, Lisa Quagliaro, et al.
Diabetes/Metabolism Research and Reviews|April 25, 2006
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metforminMatthew C Riddle, Robert R Henry, Terri H Poon, et al.
Clinical Therapeutics|March 24, 2007
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trialsJohn B Buse, David C Klonoff, Loretta L Nielsen, et al.
Pageof 2